For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.
PURPOSE To evaluate the roles of granisetron and dexamethasone for emesis control on days 2 through 7 after the administration of cisplatin in doses of 50 mg/m2 or greater to patients who had not previously received chemotherapy .  PATIENTS AND METHODS Four hundred thirty-five eligible and assessable patients were r and omized to one of two arms in a double-blind fashion : arm A ; granisetron 3 mg intravenous ( i.v . ) plus dexamethasone 10 mg i.v . prechemotherapy followed by granisetron 1 mg orally at 6 and 12 hours , then granisetron 1 mg orally and dexamethasone 8 mg orally twice daily on days 2 through 7 ( 219 patients ) ; arm B ; as in arm A but with placebo substituted for granisetron on days 2 through 7 ( 216 patients ) . All patients completed diaries in which episodes of emesis and severity of nausea were recorded . RESULTS The addition of granisetron on days 2 through 7 had no discernable impact on nausea and vomiting during this period . CONCLUSION The administration of a 5-hydroxytryptamine3 , receptor ( 5-HT3 ) antagonist , in this case granisetron , after 24 hours conferred no benefit . This negative result needs to be assessed in light of conflicting literature , but at present it does not appear that the routine use of these drugs in this setting is justified
For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .